Cargando…

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report

Herein, we report the case of an 84-year-old woman with epidermal growth factor receptor (EGFR) mutation exon 19 deletion postoperative recurrent lung adenocarcinoma. Osimertinib was administered as a first-line treatment; however, she was urgently admitted to our hospital due to dyspnea on the 46th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Yozo, Sekine, Akimasa, Hagiwara, Eri, Sato, Midori, Yamaya, Takafumi, Asaoka, Masato, Higa, Katsuyuki, Ikeda, Satoshi, Baba, Tomohisa, Komatsu, Shigeru, Iwasawa, Tae, Ogura, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349001/ https://www.ncbi.nlm.nih.gov/pubmed/34401289 http://dx.doi.org/10.1016/j.rmcr.2021.101450

Ejemplares similares

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Small-cell lung carcinoma transformation of lung adenocarcinoma diagnosed by pericardial effusion: A case report
por: Otoshi, Ryota, et al.
Publicado: (2020)

Correction to: Ultra-high-resolution computed tomography can demonstrate alveolar collapse in novel coronavirus (COVID-19) pneumonia
por: Iwasawa, Tae, et al.
Publicado: (2020)

Ultra-high-resolution computed tomography can demonstrate alveolar collapse in novel coronavirus (COVID-19) pneumonia
por: Iwasawa, Tae, et al.
Publicado: (2020)

Identification and Characteristics of Co-isolation of Multiple Nontuberculous Mycobacteria
por: Asaoka, Masato, et al.
Publicado: (2021)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Five cases of BRAF V600E-mutant lung adenocarcinoma with high expression of programmed death ligand 1
por: Katano, Takuma, et al.
Publicado: (2020)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Pneumothorax in a COVID-19 Pneumonia Patient without Underlying Risk Factors
por: Yamaya, Takafumi, et al.
Publicado: (2020)

Outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
por: Yamaya, Takafumi, et al.
Publicado: (2022)

Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases
por: Murohashi, Kota, et al.
Publicado: (2020)

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
por: Bickert, Christiane, et al.
Publicado: (2021)

In reply
por: Iwasawa, Tae, et al.
Publicado: (2020)

Unilateral Autoimmune Pulmonary Alveolar Proteinosis with Polymyositis-related Interstitial Lung Disease
por: Muto, Yutaka, et al.
Publicado: (2022)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019
por: Yamaya, Takafumi, et al.
Publicado: (2021)

COVID-19 Pneumonia Resembling an Acute Exacerbation of Interstitial Pneumonia
por: Kitayama, Takaaki, et al.
Publicado: (2020)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)
por: Araki, Taisuke, et al.
Publicado: (2023)

Usefulness and safety of transbronchial lung cryobiopsy for reassessment of treatment in the clinical course of diffuse parenchymal lung disease
por: Sato, Yozo, et al.
Publicado: (2022)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Clinical characteristics of Japanese patients with moderate to severe COVID-19
por: Otoshi, Ryota, et al.
Publicado: (2021)

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity
por: Yamanaka, Yumie, et al.
Publicado: (2017)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis
por: Mohammed, Turab, et al.
Publicado: (2021)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
por: Otoshi, Ryota, et al.
Publicado: (2019)

Disease activity of lung cancer at the time of acute exacerbation of interstitial lung disease during cytotoxic chemotherapy
por: Sekine, Akimasa, et al.
Publicado: (2022)

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
por: Itano, Junko, et al.
Publicado: (2019)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Pilot Quasi-Randomized Controlled Study of Herbal Medicine Hochuekkito as an Adjunct to Conventional Treatment for Progressed Pulmonary Mycobacterium avium Complex Disease
por: Enomoto, Yasunori, et al.
Publicado: (2014)

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure
por: Harada, Guilherme, et al.
Publicado: (2019)

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

A 16-year Follow-up Case of Interstitial Pneumonia with Systemic Sclerosis-rheumatoid Arthritis Overlap Syndrome
por: Yamakawa, Hideaki, et al.
Publicado: (2017)

Pemetrexed-induced Interstitial Lung Disease Mimicking Hypersensitivity Pneumonia: A Pathologically Proven Case
por: Otoshi, Ryota, et al.
Publicado: (2019)

A case of intrathoracic desmoid tumor with pulmonary Mycobacterium abscessus disease
por: Katano, Takuma, et al.
Publicado: (2020)

Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis
por: Yamakawa, Hideaki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3muee2qdc35g1ljpdkmanfisq0